Speech Date

2026/07/15

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for June 2026

Fact Date

2026-07-15

Describe

1.Date of occurrence of the event:2026/07/15
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of June, the Company's accounts receivable balance
is NT$3,840,442 thousand (including overdue accounts receivable
of NT$1,723,213 thousand and non-overdue accounts receivable
of NT$2,117,229 thousand), accounting for 53.18% of total assets
and 550.95% of Common Stock. The amount recieved in June
was NT$292,504 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Since 2026, the Company has strengthened its accounts receivable
collection mechanism. For overdue accounts and customers with
potential bad debt risks, the Chairman & CEO, CFO, and Financial
Analysis Manager are now responsible for tracking and supervision
based on the transaction amounts and risk levels.
Driven by the Company's proactive collection measures, accounts receivable
collections for this quarter have increased by 10.78% compared to the
previous quarter, demonstrating the effectiveness of the Company's accounts
receivable collection mechanism. Going forward, the Company will continue
to implement collection measures and strengthen the management of accounts
receivable to mitigate overall credit risk and enhance capital recovery
efficiency.

Speech Date

2026/07/14

Theme

Announcement on behalf of subsidiary Cowealth Medical China Co., Ltd. regarding the 2026 semi-annual earnings forecast

Fact Date

2026-07-14

Describe

1.Date of occurrence of the event:2026/07/14
2.Company name:Cowealth Medical China Co., Ltd (CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):Subsidiaries
4.Reciprocal shareholding ratios:Hold 54.00% shares
5.Cause of occurrence:
The subsidiary will announce its 2026 semi-annual earnings forecast in
accordance with the Rules Governing the Listing of Stocks on Shanghai
Stock Exchange.
6.Countermeasures:NA.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
Cowealth Medical China Co., Ltd. 2026 Semi-Annual Earnings Forecast
is as follows:
(1) Net Profit Attributable to Shareholders of the Listed Company:
RMB -9.0 million to -6.2 million
(2) Net Profit After Deducting Non-Recurring Gains and Losses:
RMB -9.07 million to -6.27 million
(3) Explanation of Performance Change:
(3-1) In the first half of 2026, affected by changes in the domestic
macroeconomic environment and healthcare policies such as centralized
procurement and price reductions, the product procurement prices for the
Company's hospital clients were lowered, and the scale of procurement
orders fluctuated compared to the same period last year. This led to a
decline in the Company's sales revenue. Fortunately, through the Company's
continuous optimization of supply chain management to control costs and
marketing expenses, operating profit improved, and the Company turned losses
into profits in the second quarter of this year.
(3-2) During the reporting period, the Company's estimated total expenses
decreased compared to the same period last year, indicating that expense
control has been effective. The Company's clients are primarily public
hospitals. Affected by the timing of medical insurance settlements, the
collection cycle from clients experienced certain fluctuations. The credit
impairment losses provisioned by the Company increased compared to the same
period last year, but the risk of generating bad debts remains extremely
low and is in a controllable state.
(3-3) During the reporting period, the Company continued to actively
adjust its business layout and development strategy, with sustained
investment in the iterative R&D and market expansion of ”ACME” proprietary
products. Maitawei has progressed from the technical validation stage to
the large-scale clinical stage. Meanwhile, the Company actively expanded
its market development team and enhanced high value-added services for
hospital clients, driving the growth of a second business avenue beyond
the centralized procurement segment, which lays the foundation for
profitability in future periods.
(4) Other Important Notes:
The above financial data is self-compiled by the Company and has not been
audited by a CPA firm. The actual figures shall be subject to the official
release in the Company's 2026 semi-annual report.

Speech Date

2026/06/15

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for May 2026

Fact Date

2026-06-15

Describe

1.Date of occurrence of the event:2026/06/15
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of May, the Company's accounts receivable balance
is NT$3,719,511 thousand (including overdue accounts receivable
of NT$1,725,628 thousand and non-overdue accounts receivable
of NT$1,993,883 thousand), accounting for 52.20% of total assets
and 480.25% of Common Stock. The amount recieved in May
was NT$301,653 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Since 2026, the Company has strengthened its accounts receivable
collection mechanism. For overdue accounts and customers with
potential bad debt risks, the Chairman & CEO, CFO, and Financial
Analysis Manager are now responsible for tracking and supervision
based on the transaction amounts and risk levels.
Driven by the Company's proactive collection measures, cash
collections in May have significantly increased by 36% compared to the
previous month. Going forward, the Company will continue to implement
collection measures and strengthen the management of accounts
receivable to mitigate overall credit risk and enhance capital recovery
efficiency.

Speech Date

2026/06/11

Theme

Announcement of the execution results of the fourth buyback of treasury shares

Fact Date

2026-06-11

Describe

1.Originally prescribed ceiling on total monetary
amount of share repurchase (NTD):725,311,000
2.Originally scheduled period for the repurchase:2026/06/05~2026/08/04
3.Originally determined no.of shares to be repurchased
(shares):3,485,000
4.Originally determined repurchase price range (NTD):11.00~26.00
5.Actual period of the current repurchase:2026/06/08~2026/06/11
6.No.of shares currently repurchased (shares):3,485,000
7.Total monetary amount of shares currently repurchased (NTD):57,437,233
8.Current average repurchase price per share (NTD):16.48
9.Cumulative no.of the company’s own shares held (shares):3,485,000
10.Cumulative no.of the company’s own shares as a
percentage of the total no.of the company’s issued shares (%):5.00
11.Reason for non-completion of the current share repurchase:None
12.Any other matters that need to be specified:
The number of shares repurchased reached 4% of the total issued
shares on the day of completion. Therefore, no separate
announcement will be made.

Speech Date

2026/06/10

Theme

(Supplementary Announcement on March 2, 2026) Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd.: Civil litigation

Fact Date

2026-06-10

Describe

1.Parties to the legal matter:
Plaintiff/ Defendant: Guangdong Second Provincial General Hospital
Plaintiff/ Defendant: Cowealth Medical China Co., Ltd.
2.Name of the court or punishing agency of the legal matter:
Haizhu District People’s Court of Guangzhou
3.Reference/Case number of relevant documents of the legal matter:
Civil Judgment of the Guangzhou Haizhu District People's Court
((2025) Yue 0105 Min Chu No. 15683)
4.Date of occurrence of the event:2026/06/10
5.Details of occurrence (including the matter under dispute):
The Company's subsidiary, Cowealth Medical China Co., Ltd. (hereinafter
referred to as ”The Company”) and Guangdong Second Provincial General
Hospital (hereinafter referred to as the ”Hospital”) established a
five-year reagent supply chain integration cooperation in June 2020.
Due to the Hospital's failure to purchase reagents from The Company
in full, and repeated unsuccessful negotiations, The Company filed a
lawsuit with the Haizhu District People's Court of Guangzhou Municipality
regarding a dispute over the reagent sales contract, with an amount in
dispute of RMB 48,878,323.02. The Haizhu District People's Court of
Guangzhou Municipality accepted the case on April 28, 2025. On September
10, 2025, the Hospital filed a counterclaim in relation to the same
reagent sales contract dispute, with a counterclaim amount of RMB
5,836,146. Please refer to the material information dated March 2, 2026
for details.
6.Handling procedure:
The aforementioned case has been heard by the court, and the judgment is as
follows:
1. The defendant, Guangdong Second Provincial General Hospital, shall
compensate the plaintiff, Cowealth Medical China Co., Ltd.,
for losses of RMB 3,300,000 and pay attorney fees of RMB 80,000 within ten
days from the effective date of this judgment;
2. Other litigation claims of the plaintiff, Cowealth Medical
China Co., Ltd., are dismissed;
3. All counterclaims of the counterclaim-plaintiff, Guangdong Second
Provincial General Hospital, are dismissed.
If the obligation of monetary payment is not fulfilled within the period
specified in this judgment, the debt interest during the period of delayed
performance shall be doubled.
The acceptance fee for the principal lawsuit is RMB 286,191.6, of which
RMB 266,401.6 shall be borne by the plaintiff, Cowealth Medical China
Co., Ltd., and RMB 19,790 shall be borne by the defendant,
Guangdong Second Provincial General Hospital. The aforementioned acceptance
fee has been prepaid by the plaintiff. The plaintiff agrees that the
defendant shall directly pay its share of the acceptance fee to the
plaintiff when fulfilling the obligations of this judgment. The acceptance
fee for the counterclaim is RMB 26,885.37, which shall be borne by the
counterclaim-plaintiff, Guangdong Second Provincial General Hospital.
If any party disagrees with this judgment, an appeal petition may be
submitted within 15 days from the date of service of the written judgment,
to appeal to the Guangzhou Intermediate People's Court of Guangdong Province.
7.Impact on the Company’s finance and business and projected amount:
Given that this is a first-instance judgment, both parties have the right to
appeal within the statutory period. There is uncertainty regarding the final
judgment of the case, therefore the impact on the Company's current or
subsequent profits remains uncertain. The Company has consistently taken the
initiative to maintain communication with the Hospital, striving to properly
resolve the dispute between the two parties in an amicable manner. The
Company will continue to closely monitor the subsequent progress of the case
and prudently evaluate the impact on the Company in accordance with relevant
laws, regulations, and accounting standards for business enterprises.
The Company expects that this litigation will not have a material impact on
its daily production and operations, and will fulfill its information
disclosure obligations in a timely manner in accordance with relevant
regulatory requirements.
8.Countermeasures and improvement status:
The Company has appointed legal counsel to take the necessary measures
in accordance with the relevant litigation procedures and regulations.
9.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 2
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
For details of the above announcement, please refer to the disclosure
website of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2026/06/09

Theme

Announcement of the Company's repurchase of treasury shares up to a certain standard.

Fact Date

2026-06-09

Describe

1.Date the cumulative no.of shares currently repurchased
accounted for 2 percent or more of the shares issued
by the company, or amounted to NT$300 million or more:2026/06/09
2.No.of shares currently repurchased (shares):1,401,000
3.Type of shares currently repurchased:Common shares
4.Total monetary amount of shares currently repurchased (NTD):23,076,113
5.Current average repurchase price per share (NTD):16.47
6.Cumulative no.of the company’s own shares held during
the repurchase period (shares):1,401,000
7.Cumulative no.of the company’s own shares held during
the repurchase period as a percentage of the total no.of
the company’s issued shares:2.01%
8.Any other matters that need to be specified:None

Speech Date

2026/06/05

Theme

The Board of Directors has resolved the Fourth buyback of treasury shares

Fact Date

2026-06-05

Describe

1.Date of the board of directors resolution:2026/06/05
2.Purpose of the share repurchase:
To maintain the Company’s credit and shareholders' equity.
3.Type of shares to be repurchased:Common shares
4.Ceiling on total monetary amount of share repurchase (NTD):725,311,000
5.Scheduled period for the repurchase:2026/06/05~2026/08/04
6.No.of shares to be repurchased (shares):3,485,000
7.Repurchase price range (NTD):
11.00~26.00, The Company will continue the buyback as the share price
is below the lower limit of the designated price range.
8.Method for the repurchase:
From the centralized securities exchange market
9.Shares to be repurchased as a percentage of total
issued shares of the company (%): 5%
10.Cumulative no.of the company’s own shares held
at the time of reporting (shares): 0
11.Status of repurchases within three years prior to
the time of reporting:
Actual period of the current repurchase: 2026/03/31 ~ 2026/04/14
Originally determined no.of shares to be repurchased (shares) (A): 3,872,000
No. of shares currently repurchased (shares) (B): 3,872,000
Execution status (percentage of actual shares repurchased to
originally determined) (B/A): 100%
Actual period of the current repurchase: 2026/04/29 ~ 2026/05/13
Originally determined no.of shares to be repurchased (shares) (A): 3,872,000
No. of shares currently repurchased (shares) (B): 3,872,000
Execution status (percentage of actual shares repurchased to
originally determined) (B/A): 100%
12.Status of repurchases that have been reported but
not yet completed: None.
13.Minutes of the board of directors meeting that resolved
for the share repurchase:
Minutes of the Board Meeting for Share Repurchase
The 2nd Special Meeting of the 9th Board on June 5, 2026:
Proposal: Conduct the 4th share buyback for cancellation.
Description:
1.Pursuant to Art. 28-2 of the Securities and Exchange Act and
relevant regulations, the details are as follows:
(A) Purpose: To maintain Company’s credit and shareholders’ equity.
(B) Type: Common shares.
(C) Ceiling: Statutory limit NT$725,311K; this buyback NT$90,610K.
(D) Period & Quantity: Jun 05–Aug 04, 2026; 3,485K shares.
(E) Price: NT$11–26. May continue if price is below lower limit.
(F) Method: Buyback from the OTC market.
(G) Ratio: ~5.00% (Based on 69,705,547 issued shares as of Jun 05).
(H) Current Holdings: 0 shares.
(I) Buybacks in prior 5 years:
Batch: 2nd
Actual period of buyback: 2026/03/31 ~ 2026/04/14
Actual number of shares repurchased: 3,872K shares
Status of cancellation or transfer: have been cancelled
Batch: 3rd
Actual period of buyback: 2026/04/29 ~ 2026/05/13
Actual number of shares repurchased: 3,872K shares
Status of cancellation or transfer: have been cancelled
(J) Unfinished prior buybacks: None.
(K) Board Declaration: Financial condition considered; see Att. 1.
2.Per Para. 1, Art. 28-2 of the Act, the buyback was approved
by a majority of the 2/3 directors present.
3.Chairman is authorized to handle the buyback. Execution status
will be reported at the next Shareholders' Meeting.
4.Per Para. 6, Art. 28-2 of the Act, shares held by affiliates,
directors, supervisors, managers, and their relatives shall not
be sold during the buyback period.
5.Approved by Audit Committee and submitted to the Board.
Resolution: Passed unanimously as originally proposed.
14.The Rules for Transfer of Shares set forth in Article
10 of the Regulations Governing Share Repurchase by
TWSE-listed and TPEx-Listed Companies: NA
15.The Rules for Conversion of Shares or the Rules for
Subscription of Shares set forth in Article 11 of the
Regulations Governing Share Repurchase by TWSE-listed
and TPEx-Listed Companies: NA
16.Declaration that the financial status of the company
has been considered by the board of directors, and that
its capital maintenance will not be affected:
1. The 2nd Special Meeting of the 9th Board on June 5, 2026,
attended by over 2/3 of directors and approved by a majority of
present directors, resolved to buy back 3,485,000 common shares
from the OTC market within 2 months from the reporting date.
2. The total shares to be repurchased account for only 5% of the
issued shares. The maximum amount of NT$90,610K represents only
1.65% of the Company's current assets (NT$5,501,560K) based on
the reviewed consolidated financial statements as of Mar 31, 2026.
The Board declares that the financial condition has been
considered and the buyback will not affect the maintenance of
the Company's capital.
3. This declaration was approved at the same Board meeting
with the consent of all 8 directors present (including
1 by proxy).
Cowealth Medical Holding Co., Ltd.
Chairman: Wang Chiung Chih
17.Appraisal or opinion by a CPA or securities underwriter
about the reasonableness of the share repurchase price:
According to the opinion of Grand Fortune Securities Co., Ltd.,
the price range for this share buyback is reasonable and
complies with relevant regulations.
Based on the evaluation, the impact on the Company’s financial
structure, net value per share, earnings per share (EPS),
return on equity (ROE), current ratio, quick ratio, and cash
flow is not significant to the Company’s overall financial
condition or shareholders' equity.
18.Any other matters stipulated by the SFB:None.

Speech Date

2026/06/02

Theme

(Supplementary Announcement on May 28, 2026) Completion of cancellation of repurchased treasury shares -Revised Regulatory Approval Date for Capital Reduction

Fact Date

2026-06-02

Describe

1.Date of the competent authority’s approval of capital
reduction: 2026/06/03
2.Date of completion of capitalization change registration: NA
3.Effect on the financial statements (including any
discrepancy between the amount of paid-in capital and
the no.of shares outstanding, and the effect on net
worth per share):
A total of 7,744,000 treasury shares were cancelled this time,
reducing the capital by NT$77,440,000.
The original paid-in capital was NT$774,495,470, and the paid-in capital
after capital reduction is NT$697,055,470.
4.Plan for expected exchange of shares: NA
5.Estimated no.of listed common shares after capital
reduction and new issue: NA
6.Estimated no.of listed
common shares as a percentage
of issued common shares after capital reduction and
new issue (No.of common
shares after capital reduction/No.of issued
common shares): NA
7.Countermeasures for poor circulation of equity if the
aforesaid estimated no.of
listed common shares does
not reach 5 million shares
and the percentage does not
reach 25% after capital
reduction: NA
8.Any other matters that need
to be specified:
The approval date of the capital reduction by the competent authority is
planned to be the processing date of Taipei Exchange (TPEx), which is the
(estimated) completion date for the cancellation of listed shares.

Speech Date

2026/05/28

Theme

Announcement on behalf of subsidiary Health Space (Shanghai): Cumulative disposal of financial products reaching disclosure threshold

Fact Date

2026-05-28

Describe

1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):
Structured Deposit of Xiamen International Bank (China)
2.Date of occurrence of the event: 2026/04/30~2026/05/28
3.Date of the Board of Directors’ resolution: NA
4.Other approval date: 2026/05/28
5.Volume, unit price, and total monetary amount of the transaction:
This disposal is for RMB. 18,000,000
The total cumulative disposal is RMB 36,000,000
6.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Xiamen International Bank (China) (Non-related party)
7.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer: None
8.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:
None
9.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:None
10.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained): Disposal gain of RMB 49,425
11.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions: One-time payment
12.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Expected Annualized Return of the Product as Announced by the Bank.
Processed according to the company’s approval authority.
13.Net worth per share of the Company’s underlying securities
acquired or disposed of:None
14.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
None
15.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Percentage of total assets: 2.35%
Percentage of equity of parent company: 5.78%
Working capital: NTD 3,490,583 thousand
16.Broker and broker’s fee: None
17.Concrete purpose or use of the acquisition or disposal:
RMB Structured Deposit
18.Whether the directors expressed any objection to the current
transaction:None
19.Whether the counterparty of the current transaction
is a related party:None
20.Date of ratification by supervisors or approval by
the Audit Committee:NA
21.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:None
22.Name of the CPA firm:None
23.Name of the CPA:None
24.License no.of the CPA:None
25.Whether the transaction involved in change of business model:None
26.Details on change of business model:None
27.Details on transactions with the counterparty for the past
year and the expected coming year:
Plan according to the overall financial condition of the group,
following the procedures for asset acquisition or disposal.
28.Source of funds: Operating funds
29.Date on which material information regarding the same event
has been previously released:NA
30.Any other matters that need to be specified:None

Speech Date

2026/05/28

Theme

Announcement of the completion of cancellation of repurchased treasury shares

Fact Date

2026-05-28

Describe

1.Date of the competent authority’s approval of capital
reduction: 2026/06/02
2.Date of completion of capitalization change registration: NA
3.Effect on the financial statements (including any
discrepancy between the amount of paid-in capital and
the no.of shares outstanding, and the effect on net
worth per share):
A total of 7,744,000 treasury shares were cancelled this time,
reducing the capital by NT$77,440,000.
The original paid-in capital was NT$774,495,470, and the paid-in capital
after capital reduction is NT$697,055,470.
4.Plan for expected exchange of shares: NA
5.Estimated no.of listed common shares after capital
reduction and new issue: NA
6.Estimated no.of listed
common shares as a percentage
of issued common shares after capital reduction and
new issue (No.of common
shares after capital reduction/No.of issued
common shares): NA
7.Countermeasures for poor circulation of equity if the
aforesaid estimated no.of
listed common shares does
not reach 5 million shares
and the percentage does not
reach 25% after capital
reduction: NA
8.Any other matters that need
to be specified:
The approval date of the capital reduction by the competent authority is
planned to be the processing date of Taipei Exchange (TPEx), which is the
(estimated) completion date for the cancellation of listed shares.

Speech Date

2026/05/20

Theme

Announcement of the important resolutions of 2026 annual general shareholders’ meeting

Fact Date

2026-05-20

Describe

1.Date of the shareholders' meeting:2026/05/20
2.Important resolutions I.Profit distribution/deficit compensation:
Approved the 2025 earnings distribution
3.Important resolutions II.Amendments of the company charter:
Approved the amendment to the ”Articles of Incorporation”
4.Important resolutions III.Business report and financial statements:
Approved the 2025 annual financial statements and business report
5.Important resolutions IV.Election for directors and supervisors:
Completion of the comprehensive re-election of directors (including
independent directors)
6.Important resolutions V.Other matters:
(1)Approved the amendment to the ” Procedures for Acquisition or
Disposal of Assets ”
(2)Approved the amendment to the ” Rules of Procedure for
Shareholders Meetings ”
(3)Proposal to lift the non-compete restriction imposed on the
directors of the Company’s 9th Board of Directors
7.Any other matters that need to be specified: None

Speech Date

2026/05/20

Theme

Announcement of the list of elected Directors (incl. Independent Directors) upon full re-election at the 2026 Annual General Shareholders' Meeting

Fact Date

2026-05-20

Describe

1.Date of occurrence of the change:2026/05/20
2.Elected or changed position (Please enter institutional director,
institutional supervisor, independent director, natural-person director or
natural-person supervisor):
Natural-person Director, Independent Director
3.Title, name and nationality of the previous position holder:
Director:Wang, Chiung-Chih
Director:Lee, Duen
Director:Chin, Chuan
Director:Tsao, Guang-Tsann
Independent Director:Chen, Kun-Chih
Independent Director:Lau, Ying-Tung
Independent Director:Tong, Chung-Wen
Independent Director:Chen, Shu-Hua
4.Resume of the previous position holder:
Director:Wang, Chiung-Chih
Chairman of Cowealth Medical Holding Co., Ltd.
Director:Lee, Duen
General Manager of Cowealth Medical Holding Co., Ltd.
Director:Chin, Chuan
Former General Manager of Cowealth Medical Holding Co., Ltd.
Director:Tsao, Guang-Tsann
Chairman of Chin Pao San Enterprise Co., Ltd.
Independent Director:Chen, Kun-Chih
Associate Professor, Department of Accounting, National Taiwan University
Independent Director:Lau, Ying-Tung
Former President of Chang Gung University of Science and Technology
Independent Director:Tong, Chung-Wen
Former Chief Financial Officer of Unisys Taiwan Ltd.
Independent Director:Chen, Shu-Hua
Finance and Accounting Manager, Taiwan Branch of Sennics Co., Ltd.
(Singapore)
5.Title, name and nationality of the new position holder:
Director:Wang, Chiung-Chih
Director:Lee, Duen
Director:Chou, Lu-lu
Director:Tsao, Guang-Tsann
Independent Director:Chen, Kun-Chih
Independent Director:Lau, Ying-Tung
Independent Director:Chen, Shu-Hua
Independent Director:Wu, Chih-Hsiung
6.Resume of the new position holder:
Director:Wang, Chiung-Chih
Chairman of Cowealth Medical Holding Co., Ltd.
Director:Lee, Duen
General Manager of Cowealth Medical Holding Co., Ltd.
Director:Chou, Lu-lu
Former Director of Accounting Division, TSMC
Director:Tsao, Guang-Tsann
Chairman of Chin Pao San Enterprise Co., Ltd.
Independent Director:Chen, Kun-Chih
Associate Professor, Department of Accounting, National Taiwan University
Independent Director:Lau, Ying-Tung
Former President of Chang Gung University of Science and Technology
Independent Director:Chen, Shu-Hua
CFO, Taiwan Branch of Sennics Co., Ltd. (Singapore)
Independent Director:Wu, Chih-Hsiung
CEO of Healthcare Enterprise, En Chu Kong Hospital
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”): Term expired
8.Reason for the change: Term expired
9.Number of shares held by the new position holder when elected:
Director:Wang, Chiung-Chih 6,975,186 shares
Director:Lee, Duen 9,177,834 shares
Director:Chou, Lu-lu 0 shares
Director:Tsao, Guang-Tsann 0 shares
Independent Director:Chen, Kun-Chih 0 shares
Independent Director:Lau, Ying-Tung 0 shares
Independent Director:Chen, Shu-Hua 0 shares
Independent Director:Wu, Chih-Hsiung 0 shares
10.Original term (from __________ to __________):
2023/05/24~2026/05/23
11.Effective date of the new appointment: 2026/05/20
12.Turnover rate of directors of the same term: Term expired, N/A
13.Turnover rate of independent directors of the same term:
Term expired, N/A
14.Turnover rate of supervisors of the same term:N/A
15.Change in one-third or more of directors (Please enter “Yes” or
“No”): No
16.Directors with a registered household address in ROC.does not
exceed 1/2 of the existing directors after the change (Please enter
“Yes”or ”No”,if ”yes”, please indicate the countermeasures):No
17.Only less than 2 independent directors with a registered
household address in ROC.after the change (Please enter ”Yes”
or “No”,if ”yes”, please indicate the countermeasures):No
18.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None

Speech Date

2026/05/20

Theme

Announcement of the election of the Chairman by the Board of Directors of the Company

Fact Date

2026-05-20

Describe

1.Date of the board of directors resolution or date of occurrence of the
change:2026/05/20
2.Position (Please enter chairperson or president/general manager):
Chairman
3.Name of the previous position holder:Wang, Chiung-Chih
4.Resume of the previous position holder:
Chairman of Cowealth Medical Holding Co., Ltd.
5.Name of the new position holder:Wang, Chiung-Chih
6.Resume of the new position holder:
Chairman of Cowealth Medical Holding Co., Ltd.
7.Circumstances of change (Please enter ”resignation”, ”dismissal”,
”term expired” , ”job relocation”, ”severance”, ”retirement”,
”death” or ”new appointment”):Term expired.
8.Reason for the change:Term expired.
9.Effective date of the new appointment:2026/05/20
10.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None

Speech Date

2026/05/20

Theme

Announcement of the resolution by the Board of Directors to appoint members of the 9th term Audit Committee

Fact Date

2026-05-20

Describe

1.Date of occurrence of the change:2026/05/20
2.Name of the functional committees:Audit Committee
3.Name of the previous position holder:
Mr. Chen, Kun-Chih
Mr. Lau, Ying-Tung
Ms. Tong, Chung-Wen
Ms. Chen, Shu-Hua
4.Resume of the previous position holder:
Mr. Chen, Kun-Chih
Associate Professor, Department of Accounting, National Taiwan University
Mr. Lau, Ying-Tung
Former President of Chang Gung University of Science and Technology
Ms. Tong, Chung-Wen
Former CFO of Unisys Taiwan Ltd.
Ms. Chen, Shu-Hua
Finance and Accounting Manager, Taiwan Branch of Sennics Co.,Ltd.
(Singapore)
5.Name of the new position holder:
Mr. Chen, Kun-Chih
Mr. Lau, Ying-Tung
Ms. Chen, Shu-Hua
Mr. Wu, Chih-Hsiung
6.Resume of the new position holder:
Mr. Chen, Kun-Chih
Associate Professor, Department of Accounting, National Taiwan University
Mr. Lau, Ying-Tung
Former President of Chang Gung University of Science and Technology
Ms. Chen, Shu-Hua
CFO, Taiwan Branch of Sennics Co., Ltd. (Singapore)
Mr. Wu, Chih-Hsiung
CEO of Healthcare Enterprise, En Chu Kong Hospital
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):Term expired
8.Reason for the change:Term expired
9.Original term (from __________ to __________):2023/05/24~2026/05/23
10.Effective date of the new member:2026/05/20
11.Any other matters that need to be specified:
The term of the members of the 9th term Audit Committee is
from May 20, 2026 to May 19, 2029.

Speech Date

2026/05/20

Theme

Announcement of the resolution by the Board of Directors to appoint members of the 9th term Remuneration Committee

Fact Date

2026-05-20

Describe

1.Date of occurrence of the change:2026/05/20
2.Name of the functional committees:Remuneration Committee
3.Name of the previous position holder:
Mr. Lau, Ying-Tung
Ms. Tong, Chung-Wen
Ms. Chen, Shu-Hua
4.Resume of the previous position holder:
Mr. Lau, Ying-Tung
Former President of Chang Gung University of Science and Technology
Ms. Tong, Chung-Wen
Former CFO of Unisys Taiwan Ltd.
Ms. Chen, Shu-Hua
Finance and Accounting Manager, Taiwan Branch of Sennics Co.,Ltd.
(Singapore)
5.Name of the new position holder:
Mr. Lau, Ying-Tung
Ms. Chen, Shu-Hua
Mr. Wu, Chih-Hsiung
6.Resume of the new position holder:
Mr. Lau, Ying-Tung
Former President of Chang Gung University of Science and Technology
Ms. Chen, Shu-Hua
CFO, Taiwan Branch of Sennics Co., Ltd. (Singapore)
Mr. Wu, Chih-Hsiung
CEO of Healthcare Enterprise, En Chu Kong Hospital
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):Term expired
8.Reason for the change:Term expired
9.Original term (from __________ to __________):2023/05/24~2026/05/23
10.Effective date of the new member:2026/05/20
11.Any other matters that need to be specified:
The term of the members of the 9th term Remuneration Committee is from
May 20, 2026 to May 19, 2029.

Speech Date

2026/05/20

Theme

Resolution of 2026 Shareholders' Meeting to release newly elected Directors (incl. Independent Directors) from non-competition restrictions

Fact Date

2026-05-20

Describe

1.Date of the shareholders' meeting resolution:2026/05/20
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
(1)Director:Wang, Chiung-Chih
(2)Director:Lee, Duen
(3)Director:Tsao, Guang-Tsann
(4)Director:Chou, Lu-lu
(5)Independent Director:Chen, Kun-Chih
(6)Independent Director:Chen, Shu-Hua
(7)Independent Director:Wu, Chih-Hsiung
3.Items of competitive conduct in which the officer is
permitted to engage:
A director engaging in activities within the company's scope of business for
themselves or others shall be limited to actions that do not harm the
interests of the company.
(1)Director:Wang, Chiung-Chih
Director of Cowealth Medical China Co., Ltd.
(2)Director:Lee, Duen
Chairman of Cowealth Medical China Co., Ltd.
(3)Director:Tsao, Guang-Tsann
Chairman of Chin Pao San Enterprise Co., Ltd.
Chairman of Yu Yue Art Development Co., Ltd.
Chairman of Yu Yue Investment Enterprise Co., Ltd.
Chairman of Tzu Kuang International Investment Co., Ltd.
Chairman of Light of Taiwan Art Development Co., Ltd.
Chairman of Cowealth Run Sheng Enterprise Co., Ltd.
Director of Chin Pao Hsuan Enterprise Co., Ltd.
Director of Chen Chi Construction Co., Ltd.
Director of Chin Pao San Cultural and Tourism Enterprise Co., Ltd.
Director of Chao Jih Kuang Investment Enterprise Co., Ltd.
Director of Chin Ta Jen Enterprise Co., Ltd.
(4)Director:Chou, Lu-lu
Independent Director of AP Memory Technology Corp.
(5)Independent Director:Chen, Kun-Chih
Independent Director of AAEON Technology Inc.
(6)Independent Director:Chen, Shu-Hua
CFO, Taiwan Branch of Sennics Co., Ltd. (Singapore)
(7)Independent Director:Wu, Chih-Hsiung
Chief Executive Officer of Medical Services, En Chu Kong Hospital
Attending Physician of Breast Surgery, En Chu Kong Hospital
4.Period of permission to engage in the competitive conduct:
During the term of office as a Director or Independent Director
of the Company.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
Pursuant to Article 209 of the Company Act, the proposal was
approved as proposed by a vote at the Company's 2026 Annual
General Shareholders' Meeting.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter “N/A” below):
Director:Wang, Chiung-Chih
Director:Lee, Duen
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:
Director:Wang, Chiung-Chih
Director of Cowealth Medical China Co., Ltd.
Director:Lee, Duen
Chairman of Cowealth Medical China Co., Ltd.
8.Address of the mainland China enterprise:
Cowealth Medical China Co., Ltd.: Guangqi Building, No. 456
Hongcao Road, Xuhui District, Shanghai, China
9.Operations of the mainland China enterprise:
Cowealth Medical China Co., Ltd.: Engaged in international and
intra-zone trade, trade agency, wholesale, and product after-
sales services for medical equipment, reagents, and related
spare parts.
10.Impact on the company’s finance and business:None
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:None
12.Any other matters that need to be specified:None

Speech Date

2026/05/20

Theme

Announcement of the resolution by the Board of Directors on capital reduction through cancellation of treasury shares

Fact Date

2026-05-20

Describe

1.Date of the board of directors resolution:2026/05/20
2.Reason for capital reduction:
To cancel the treasury shares repurchased by the company in accordance
with Article 28-2 of the Securities and Exchange Act.
3.Amount of capital reduction:NTD 77,440,000
4.Cancelled shares:7,744,000 shares
5.Capital reduction ratio:10.00%
6.Share capital after capital reduction:NTD 697,055,470
7.Scheduled date of the shareholders’ meeting:NA
8.Estimated no.of TPEx-listed common shares after issuance
of new shares upon capital reduction:N/A
9.Estimated ratio of TPEx-listed common shares after issuance
of new shares upon capital reduction to outstanding common
shares:N/A
10.Please explain any countermeasures for lower circulation
in shareholding if the aforesaid estimated no.of TPEx-listed
common shares upon capital reduction does not reach 5 million
and the ratio does not reach 25%:N/A
11.Record date of capital reduction:2026/05/22
12.Any other matters that need to be specified:None

Speech Date

2026/05/15

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for April 2026

Fact Date

2026-05-15

Describe

1.Date of occurrence of the event:2026/05/15
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of April, the Company's accounts receivable balance
is NT$3,745,098 thousand (including overdue accounts receivable
of NT$1,715,850 thousand and non-overdue accounts receivable
of NT$2,029,248 thousand), accounting for 52.69% of total assets
and 483.55% of Common Stock. The amount recieved in April
was NT$220,932 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Since 2026, the Company has strengthened its accounts receivable
collection mechanism. For overdue accounts and customers with
potential bad debt risks, the Chairman & CEO, CFO, and Financial
Analysis Manager are now responsible for tracking and supervision
based on the transaction amounts and risk levels.
Under the Company's proactive collection efforts, subsequent to the
reporting period and up to today, the Company has engaged in accounts
receivable factoring with recourse, and certain hospitals have committed
to prioritizing the repayment of the Company's overdue accounts. The
total amount affected by these measures is approximately RMB 10
million. The Company continues to actively implement various collection
measures to effectively mitigate overall credit risk and safeguard
shareholders' interests.

Speech Date

2026/05/14

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the first quarter of 2026

Fact Date

2026-05-14

Describe

1.Date of the board of directors submitted or approved:2026/05/14
2.Date of the audit committee approved:2026/05/14
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2026/01/01~2026/03/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):702,143
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):116,034
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):-55,784
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):-56,959
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):-50,241
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):-31,157
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):-0.40
11.Total assets end of the period (thousand NTD):7,176,591
12.Total liabilities end of the period
(thousand NTD):2,036,313
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,910,257
14.Any other matters that need to be specified:None

Speech Date

2026/05/14

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2026-05-14

Describe

1.Date of occurrence of the event:2026/05/14
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Colab Reserch & Development Inc.
(2)Relationship with lender:
Lender:Cowealth Medical China Co., Ltd.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):1,935,800
(4)Starting outstanding balance (thousand NTD):0
(5)New loan (thousand NTD):184,756
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:184,756
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):45,279
(2)Cumulative gains/losses (thousand NTD):-11,278
5.Method of calculation of interest:
Not lower than the average interest rate on short-term debt from financial
institutions at the time of lending.
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):2,287,715
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.79
9.Sources of funds for the company to extend monetary
loans to others:Financial Institutions and Parent company
10.Any other matters that need to be specified:
The original lending limit was due to expire on May 13, 2026.
It has been early repayment and cancelled before the Board of Directors.
This is a new application for a lending limit.

Speech Date

2026/05/14

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2026-05-14

Describe

1.Date of occurrence of the event:2026/05/14
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Coaim Information Technology Co., Ltd.
(2)Relationship with lender:
Lender:Colab Reserch & Development Inc.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):202,544
(4)Starting outstanding balance (thousand NTD):0
(5)New loan (thousand NTD):138,567
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:138,567
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):158,694
(2)Cumulative gains/losses (thousand NTD):-1,414
5.Method of calculation of interest:
Not lower than the average interest rate on short-term debt from financial
institutions at the time of lending.
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):2,287,715
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.79
9.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds
10.Any other matters that need to be specified:The original lending limit
was due to expire on May 12, 2026. It has been early repayment and
cancelled before the Board of Directors. This is a new application for
a lending limit.

Speech Date

2026/05/13

Theme

Announcement of the execution results of the third buyback of treasury shares

Fact Date

2026-05-13

Describe

1.Originally prescribed ceiling on total monetary
amount of share repurchase (NTD):756,468,000
2.Originally scheduled period for the repurchase:2026/04/28~2026/06/26
3.Originally determined no.of shares to be repurchased
(shares):3,872,000
4.Originally determined repurchase price range (NTD):14.00~28.00
5.Actual period of the current repurchase:2026/04/29~2026/05/13
6.No.of shares currently repurchased (shares):3,872,000
7.Total monetary amount of shares currently repurchased (NTD):77,641,809
8.Current average repurchase price per share (NTD):20.05
9.Cumulative no.of the company’s own shares held (shares):7,744,000
10.Cumulative no.of the company’s own shares as a
percentage of the total no.of the company’s issued shares (%):10.00
11.Reason for non-completion of the current share repurchase:None
12.Any other matters that need to be specified:None

Speech Date

2026/05/08

Theme

Announcement of the Company's repurchase of treasury shares up to a certain standard. repurchase Company shares

Fact Date

2026-05-08

Describe

1.Date the cumulative no.of shares currently repurchased
accounted for 2 percent or more of the shares issued
by the company, or amounted to NT$300 million or more:2026/05/08
2.No.of shares currently repurchased (shares):1,250,000
3.Type of shares currently repurchased:Common shares
4.Total monetary amount of shares currently repurchased (NTD):25,160,998
5.Current average repurchase price per share (NTD):20.13
6.Cumulative no.of the company’s own shares held during
the repurchase period (shares):3,128,000
7.Cumulative no.of the company’s own shares held during
the repurchase period as a percentage of the total no.of
the company’s issued shares:4.04%
8.Any other matters that need to be specified:None

Speech Date

2026/05/07

Theme

Announcement of the Company's repurchase of treasury shares up to a certain standard. repurchase Company shares

Fact Date

2026-05-07

Describe

1.Date the cumulative no.of shares currently repurchased
accounted for 2 percent or more of the shares issued
by the company, or amounted to NT$300 million or more:2026/05/07
2.No.of shares currently repurchased (shares):1,878,000
3.Type of shares currently repurchased:Common shares
4.Total monetary amount of shares currently repurchased (NTD):37,455,894
5.Current average repurchase price per share (NTD):19.94
6.Cumulative no.of the company’s own shares held during
the repurchase period (shares):1,878,000
7.Cumulative no.of the company’s own shares held during
the repurchase period as a percentage of the total no.of
the company’s issued shares:2.42%
8.Any other matters that need to be specified:None

Speech Date

2026/05/06

Theme

Announcement for the Board of Directors meeting date of 2026Q1 Consolidated Financial Report

Fact Date

2026-05-06

Describe

1.Date of a notice of the board of directors meeting is issued:2026/05/06
2.Expected date of the board of directors meeting is convened:2026/05/14
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:2026Q1 consolidated financial report
4.Any other matters that need to be specified:None

Speech Date

2026/04/30

Theme

Announcement on Behalf of Important Subsidiary Health Space (Shanghai) on Cumulative Acquisition of Financial Products Reaching Disclosure Threshold

Fact Date

2026-04-30

Describe

1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):
Structured Deposit of Xiamen International Bank (China)
2.Date of occurrence of the event: 2026/04/02~2026/04/30
3.Date of the Board of Directors’ resolution: NA
4.Other approval date: 2026/04/30
5.Volume, unit price, and total monetary amount of the transaction:
This purchase is for RMB 18,000,000
The total cumulative purchase is RMB 36,000,000
6.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Xiamen International Bank (Non-related party)
7.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer: None
8.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:
None
9.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:None
10.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):None
11.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions: One-time payment
12.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Expected Annualized Return of the Product as Announced by the Bank.
Processed according to the company’s approval authority.
13.Net worth per share of the Company’s underlying securities
acquired or disposed of:None
14.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative holding amount:RMB 36,000,000
Restricted rights: RMB 0
15.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Percentage of total assets: 2.37%
Percentage of equity of parent company: 5.81%
Working capital: NTD 3,538,308 thousand
16.Broker and broker’s fee: None
17.Concrete purpose or use of the acquisition or disposal:
RMB Structured Deposit
18.Whether the directors expressed any objection to the current
transaction:None
19.Whether the counterparty of the current transaction
is a related party:None
20.Date of ratification by supervisors or approval by
the Audit Committee:NA
21.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:None
22.Name of the CPA firm:None
23.Name of the CPA:None
24.License no.of the CPA:None
25.Whether the transaction involved in change of business model:None
26.Details on change of business model:None
27.Details on transactions with the counterparty for the past
year and the expected coming year:
Plan according to the overall financial condition of the group,
following the procedures for asset acquisition or disposal.
28.Source of funds: Operating funds
29.Date on which material information regarding the same event
has been previously released:NA
30.Any other matters that need to be specified:None

Speech Date

2026/04/28

Theme

The Board of Directors has resolved the third buyback of treasury shares

Fact Date

2026-04-28

Describe

1.Date of the board of directors resolution:2026/04/28
2.Purpose of the share repurchase:
To maintain the Company’s credit and shareholders' equity.
3.Type of shares to be repurchased:Common shares
4.Ceiling on total monetary amount of share repurchase (NTD):756,468,000
5.Scheduled period for the repurchase:2026/04/28~2026/06/26
6.No.of shares to be repurchased (shares):3,872,000
7.Repurchase price range (NTD):
14.00~28.00, The Company will continue the buyback as the share price
is below the lower limit of the designated price range.
8.Method for the repurchase:
From the centralized securities exchange market
9.Shares to be repurchased as a percentage of total
issued shares of the company (%): 5%
10.Cumulative no.of the company’s own shares held
at the time of reporting (shares): 3,872,000
11.Status of repurchases within three years prior to
the time of reporting:
Actual period of the current repurchase: 2026/03/31 ~ 2026/04/14
Originally determined no.of shares to be repurchased (shares) (A): 3,872,000
No. of shares currently repurchased (shares) (B): 3,872,000
Execution status (percentage of actual shares repurchased to
originally determined) (B/A): 100%
12.Status of repurchases that have been reported but
not yet completed: None.
13.Minutes of the board of directors meeting that resolved
for the share repurchase:
Minutes of the Board Meeting for Share Repurchase
The 24rd Special Meeting of the 8th Board on April 28, 2026:
Proposal: Conduct the 3rd share buyback for cancellation.
Description:
1.Pursuant to Art. 28-2 of the Securities and Exchange Act and
relevant regulations, the details are as follows:
(A) Purpose: To maintain Company’s credit and shareholders’ equity.
(B) Type: Common shares.
(C) Ceiling: Statutory limit NT$756,467K; this buyback NT$108,416K.
(D) Period & Quantity: Apr 28–Jun 26, 2026; 3,872K shares.
(E) Price: NT$14–28. May continue if price is below lower limit.
(F) Method: Buyback from the OTC market.
(G) Ratio: ~5.00% (Based on 77,449,547 issued shares as of Apr 28).
(H) Current Holdings: 3,872K shares.
(I) Buybacks in prior 5 years:
Batch: 2nd
Actual period of buyback: 2026/03/31 ~ 2026/04/14
Actual number of shares repurchased: 3,872K shares
Status of cancellation or transfer: Not yet canceled
(J) Unfinished prior buybacks: None.
(K) Board Declaration: Financial condition considered; see Att. 1.
2.Per Para. 1, Art. 28-2 of the Act, the buyback was approved
by a majority of the 2/3 directors present.
3.Chairman is authorized to handle the buyback. Execution status
will be reported at the next Shareholders' Meeting.
4.Per Para. 6, Art. 28-2 of the Act, shares held by affiliates,
directors, supervisors, managers, and their relatives shall not
be sold during the buyback period.
5.Approved by Audit Committee and submitted to the Board.
Resolution: Passed unanimously as originally proposed.
14.The Rules for Transfer of Shares set forth in Article
10 of the Regulations Governing Share Repurchase by
TWSE-listed and TPEx-Listed Companies: NA
15.The Rules for Conversion of Shares or the Rules for
Subscription of Shares set forth in Article 11 of the
Regulations Governing Share Repurchase by TWSE-listed
and TPEx-Listed Companies: NA
16.Declaration that the financial status of the company
has been considered by the board of directors, and that
its capital maintenance will not be affected:
1. The 24rd Special Meeting of the 8th Board on April 28, 2026,
attended by over 2/3 of directors and approved by a majority of
present directors, resolved to buy back 3,872,000 common shares
from the OTC market within 2 months from the reporting date.
2. The total shares to be repurchased account for only 5% of the
issued shares. The maximum amount of NT$108,416K represents only
1.97% of the Company's current assets (NT$5,513,051K) based on
the audited consolidated financial statements as of Dec 31, 2025.
The Board declares that the financial condition has been
considered and the buyback will not affect the maintenance of
the Company's capital.
3. This declaration was approved at the same Board meeting
with the consent of all 8 directors present (including
1 by proxy).
Cowealth Medical Holding Co., Ltd.
Chairman: Wang Chiung Chih
17.Appraisal or opinion by a CPA or securities underwriter
about the reasonableness of the share repurchase price:
According to the opinion of Grand Fortune Securities Co., Ltd.,
the price range for this share buyback is reasonable and
complies with relevant regulations.
Based on the evaluation, the impact on the Company’s financial
structure, net value per share, earnings per share (EPS),
return on equity (ROE), current ratio, quick ratio, and cash
flow is not significant to the Company’s overall financial
condition or shareholders' equity.
18.Any other matters stipulated by the SFB:None.

Speech Date

2026/04/23

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2026-04-23

Describe

1.Date of occurrence of the event:2026/04/23
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 54.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the 2026 First Quarter Report of the Company
2、Resolutions Regarding the 2025 Sustainability Report of the Company
3、Resolutions Regarding the Appointment of the Securities Affairs
Representative
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2026/04/23

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions of 2025 annual general shareholders’ meeting

Fact Date

2026-04-23

Describe

1.Date of the shareholders' meeting:2026/04/23
2.Important resolutions I.Profit distribution/deficit compensation:
Approval of the ”Resolutions Regarding the 2025 Earnings Distribution
Plan of the Company”
3.Important resolutions II.Amendments of the company charter:
None.
4.Important resolutions III.Business report and financial statements:
None.
5.Important resolutions IV.Election for directors and supervisors:
None.
6.Important resolutions V.Other matters:
(1)Approval of the ”Resolutions Regarding the 2025 Board of Directors'
Work Report of the Company”
(2)Approval of the ”Resolutions Regarding the 2025 Independent Directors'
Performance Report of the Company”
(3)Approval of the ”Resolutions Regarding the Amendments to the
Management Regulations Governing the Remuneration of Directors”
(4)Approval of the “Resolutions Regarding the Proposal for the Company's
Director Remuneration Plan for the Year 2026”
(5)Approval of the ”Resolutions Regarding the Plan for the Guarantee
Quota for the Year 2026 of the Company”
(6)Approval of the “Resolutions Regarding the Proposal for the Company's
Application for Credit Line from Banks and Other Financial
Institutions”
7.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2026/04/22

Theme

(Amended March 30)Board of Directors resolved to supplement the notice for the 2026 Annual General Shareholders’ Meeting(Additions to agenda)

Fact Date

2026-03-30

Describe

1.Date of the board of directors' resolution：2026/03/30
2.Shareholders meeting date：2026/05/20
3.Shareholders meeting location：Cowealth Center of 23F, No. 76,Sec. 2, Dunhua S. Rd., Da’an Dist.,
Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting)：physical shareholders' meeting
5.Cause for convening the meeting (1)：Report item(s)
(1)：2025annual business report
(2)：Audit Committee's review of the 2025 annual final accounting books
and statements
(3)：Report on 2025 employees' and directors' remuneration
(4)：Report on 2025 director compensation
(5)：Report on communications between the Audit Committee and the Head of
Internal Audit for 2025
(6)：Report on the 2026 concrete implementation plan for sustainable
development
(7)：Report on the 2026 share buyback progress
6.Cause for convening the meeting (2)：Ratification Item(s)
(1)：2025 annual financial statements and business report
(2)：2025 earnings distribution
7.Cause for convening the meeting (3)：Discussion Item(s)
(1)：Amendments to the "Articles of Association"
(2)：Amendments to the "Procedures for Acquisition or Disposal of Assets
Management"
(3)：Amendments to the "The Rules of Procedure for Shareholders Meetings"
8.Cause for convening the meeting (4)：Election Item
(1)：Proposal for Full Re-election of the Board of Directors
9.Cause for convening the meeting (5)：Other Proposal(s)
(1)：Removal of Non-Compete Restrictions for the 9th Board Directors of the Company
10.Extemporary Motions：
11.Book closure starting date：2026/03/22
12.Book closure ending date：2026/05/20
13.Any other matters that need to be specified：In accordance with the laws of the Republic of China, the
following matters related to the acceptance of shareholder
proposals in writing are established:
(1)Acceptance period: From March 6, 2026, to March 16, 2026.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Cowealth Holing Company
(4) Proposal Eligibility: Shareholders who hold more than 1% of
the total issued shares (whether individually or collectively).
(5) Proposal Method:
Shareholders intending to submit a proposal must do so in
writing by 5:00 PM on March 16, 2026, and each shareholder may
submit only one proposal. Proposals exceeding one item will not
be included in the agenda. Each proposal shall be limited to 300
Chinese characters; proposals exceeding this limit will not be
included in the agenda.
(6) Other Matters Related to Shareholder Proposals: Any matters
not covered regarding shareholder proposals will be handled
according to relevant laws and regulations. Whether or not a
proposal will be excluded from the agenda according to the
company's articles of association will be reviewed by the board
of directors after the proposal acceptance period has ended.
The detailed content of the accepted proposals will be based on
the company's public announcements on the Market Observation
Post System.
For this shareholder meeting, shareholders will exercise
their voting rights electronically. Relevant details are as
follows:
(1) Voting Period: Extended from March 6, 2026, to March 26, 2026.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(Taiwan Branch of Cowealth Holing Company)
(3) Proposal Eligibility: Shareholders who hold more than 1% of
the total issued shares (whether individually or collectively).
(4) Nomination Method:
There are four director positions and four independent director
positions to be elected. Shareholders intending to nominate
candidates for directors (including independent directors) must
submit a written nomination by 5:00 PM on March 26, 2026,
including the nominator's information and the nominee's name,
educational and professional background, and supporting
documents demonstrating compliance with the qualifications for
independent directors. Nominations exceeding the number of
positions to be elected, or nominees not meeting statutory
qualifications, will not be included in the candidate list.

Electronic Voting for the Shareholders' Meeting
(1) Voting Period: From April 20, 2026, to May 17, 2026.
(2) Electronic Voting Platform: Taiwan Depository & Clearing
Corporation, website: https://www.stockvote.com.tw

Speech Date

2026/04/21

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. to hold 2025 annual performance conference

Fact Date

2026-04-21

Describe

1.Date and time that the Company disclose its financial
or business information to the public:2026/04/21
2.Location that the Company disclose its financial or
business information to the public: Web conference
3.Financial/Business data to be disclosed:
Operating results and financial position for 2025 annual
4.Content of press release, if provided: NA
5.Any other matters that need to be specified:
Date and time of conference：2026/04/28(Tuesday) 11:30-12:30
Online platform：https://www.ir-online.cn
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2026/04/17

Theme

Announcement of the execution results of the 2nd buyback (Correcting actual period and stating that the quantity reached 4% of issued shares)

Fact Date

2026-04-17

Describe

1.Originally prescribed ceiling on total monetary
amount of share repurchase (NTD):756,468,000
2.Originally scheduled period for the repurchase:2026/03/30~2026/05/29
3.Originally determined no.of shares to be repurchased
(shares):3,872,000
4.Originally determined repurchase price range (NTD):14.00~30.00
5.Actual period of the current repurchase:2026/03/31~2026/04/14
6.No.of shares currently repurchased (shares):3,872,000
7.Total monetary amount of shares currently repurchased (NTD):76,757,898
8.Current average repurchase price per share (NTD):19.82
9.Cumulative no.of the company’s own shares held (shares):3,872,000
10.Cumulative no.of the company’s own shares as a
percentage of the total no.of the company’s issued shares (%):5.00
11.Reason for non-completion of the current share repurchase:None
12.Any other matters that need to be specified:
The number of shares repurchased reached 4% of the total issued
shares on the day of completion. Therefore, no separate
announcement will be made.

Speech Date

2026/04/15

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for March 2026

Fact Date

2026-04-15

Describe

1.Date of occurrence of the event:2026/04/15
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of March, the Company's accounts receivable balance
is NT$3,668,861 thousand (including overdue accounts receivable
of NT$1,708,289 thousand and non-overdue accounts receivable
of NT$1,960,572 thousand), accounting for 50.99% of total assets
and 473.71% of Common Stock. The amount recieved in March
was NT$387,348 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Since 2026, the Company has strengthened its accounts receivable
collection mechanism. For overdue accounts and customers with
potential bad debt risks, the Chairman & CEO, CFO, and Financial
Analysis Manager are now responsible for tracking and supervision
based on the transaction amounts and risk levels.
In March, overdue accounts receivable decreased significantly by 13%
compared to the previous month, demonstrating the effectiveness of
the Company's collection mechanism. The Company will continue to
implement collection measures and enhance accounts receivable
management to mitigate overall credit risk and improve capital
recovery efficiency.

Speech Date

2026/04/15

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the 2025 shareholders' meeting location and related matters

Fact Date

2026-03-13

Describe

1.Date of the board of directors resolution:2026/03/13
2.General shareholders' meeting date:2026/04/23
3.General shareholders' meeting location:
20F Conference room of Guangqi Building, No. 456, Hongcao Rd., Xuhui Dist.,
Shanghai, China
4.Cause for convening the meeting I.Reported matters:None
5.Cause for convening the meeting II.Acknowledged matters:None
6.Cause for convening the meeting III, Matters for Discussion:
(1)Resolutions Regarding the 2025 Board of Directors' Work Report
of the Company
(2)Resolutions Regarding the 2025 Independent Directors' Performance Report
of the Company
(3)Resolutions Regarding the Amendments to the Management
Regulations Governing the Remuneration of Directors
(4)Resolutions Regarding the Proposal for the Company's
Director Remuneration Plan for the Year 2026
(5)Resolutions Regarding the 2025 Earnings Distribution Plan
of the Company
(6)Resolutions Regarding the Plan for the Guarantee Quota for
the Year 2026 of the Company
(7)Resolutions Regarding the Proposal for the Company's
Application for Credit Line from Banks and Other Financial
Institutions
7.Cause for convening the meeting IV.Election matters:None
8.Cause for convening the meeting V.Other Proposals:None
9.Cause for convening the meeting VI.Extemporary Motions:None
10.Book closure starting date:NA
11.Book closure ending date:NA
12.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2026/04/14

Theme

Announcement of the execution results of the second buyback of treasury shares

Fact Date

2026-04-14

Describe

1.Originally prescribed ceiling on total monetary
amount of share repurchase (NTD):756,468,000
2.Originally scheduled period for the repurchase:2026/03/30~2026/05/29
3.Originally determined no.of shares to be repurchased
(shares):3,872,000
4.Originally determined repurchase price range (NTD):14.00~30.00
5.Actual period of the current repurchase:2026/03/30~2026/04/14
6.No.of shares currently repurchased (shares):3,872,000
7.Total monetary amount of shares currently repurchased (NTD):76,757,898
8.Current average repurchase price per share (NTD):19.82
9.Cumulative no.of the company’s own shares held (shares):3,872,000
10.Cumulative no.of the company’s own shares as a
percentage of the total no.of the company’s issued shares (%):5.00
11.Reason for non-completion of the current share repurchase:None
12.Any other matters that need to be specified:None

Speech Date

2026/04/09

Theme

Announcement of the Company's repurchase of treasury shares up to a certain standard.

Fact Date

2026-04-09

Describe

1.Date the cumulative no.of shares currently repurchased
accounted for 2 percent or more of the shares issued
by the company, or amounted to NT$300 million or more:2026/04/09
2.No.of shares currently repurchased (shares):1,605,000
3.Type of shares currently repurchased:Common shares
4.Total monetary amount of shares currently repurchased (NTD):31,189,650
5.Current average repurchase price per share (NTD):19.43
6.Cumulative no.of the company’s own shares held during
the repurchase period (shares):1,605,000
7.Cumulative no.of the company’s own shares held during
the repurchase period as a percentage of the total no.of
the company’s issued shares:2.07%
8.Any other matters that need to be specified:None

Speech Date

2026/03/31

Theme

The Board of Directors has resolved the second buyback of treasury shares

Fact Date

2026-03-30

Describe

1.Date of the board of directors resolution:2026/03/30
2.Purpose of the share repurchase:
To maintain the Company’s credit and shareholders' equity.
3.Type of shares to be repurchased:Common shares
4.Ceiling on total monetary amount of share repurchase (NTD):756,468,000
5.Scheduled period for the repurchase:2026/03/30~2026/05/29
6.No.of shares to be repurchased (shares):3,872,000
7.Repurchase price range (NTD):
14.00~30.00, The Company will continue the buyback as the share price
is below the lower limit of the designated price range.
8.Method for the repurchase:
From the centralized securities exchange market
9.Shares to be repurchased as a percentage of total
issued shares of the company (%): 5%
10.Cumulative no.of the company’s own shares held
at the time of reporting (shares): 0
11.Status of repurchases within three years prior to
the time of reporting: None.
12.Status of repurchases that have been reported but
not yet completed: None.
13.Minutes of the board of directors meeting that resolved
for the share repurchase:
Minutes of the Board Meeting for Share Repurchase
The 23rd Special Meeting of the 8th Board on March 30, 2026:
Proposal: Conduct the 2nd share buyback for cancellation.
Description:
1.Pursuant to Art. 28-2 of the Securities and Exchange Act and
relevant regulations, the details are as follows:
(A) Purpose: To maintain Company’s credit and shareholders’ equity.
(B) Type: Common shares.
(C) Ceiling: Statutory limit NT$756,468K; this buyback NT$116,160K.
(D) Period & Quantity: Mar 30–May 29, 2026; 3,872K shares.
(E) Price: NT$14–30. May continue if price is below lower limit.
(F) Method: Buyback from the OTC market.
(G) Ratio: ~5.00% (Based on 77,449,547 issued shares as of Mar 30).
(H) Current Holdings: 0 shares.
(I) Buybacks in prior 5 years: None.
(J) Unfinished prior buybacks: None.
(K) Board Declaration: Financial condition considered; see Att. 1.
2.Per Para. 1, Art. 28-2 of the Act, the buyback was approved
by a majority of the 2/3 directors present.
3.Chairman is authorized to handle the buyback. Execution status
will be reported at the next Shareholders' Meeting.
4.Per Para. 6, Art. 28-2 of the Act, shares held by affiliates,
directors, supervisors, managers, and their relatives shall not
be sold during the buyback period.
5.Approved by Audit Committee and submitted to the Board.
Resolution: Passed unanimously as originally proposed.
14.The Rules for Transfer of Shares set forth in Article
10 of the Regulations Governing Share Repurchase by
TWSE-listed and TPEx-Listed Companies: NA
15.The Rules for Conversion of Shares or the Rules for
Subscription of Shares set forth in Article 11 of the
Regulations Governing Share Repurchase by TWSE-listed
and TPEx-Listed Companies: NA
16.Declaration that the financial status of the company
has been considered by the board of directors, and that
its capital maintenance will not be affected:
1. The 23rd Special Meeting of the 8th Board on March 30, 2026,
attended by over 2/3 of directors and approved by a majority of
present directors, resolved to buy back 3,872,000 common shares
from the OTC market within 2 months from the reporting date.
2. The total shares to be repurchased account for only 5% of the
issued shares. The maximum amount of NT$116,160K represents only
2.11% of the Company's current assets (NT$5,513,051K) based on
the audited consolidated financial statements as of Dec 31, 2025.
The Board declares that the financial condition has been
considered and the buyback will not affect the maintenance of
the Company's capital.
3. This declaration was approved at the same Board meeting with
the consent of all 8 directors present.
Cowealth Medical Holding Co., Ltd.
Chairman: Wang Chiung Chih
17.Appraisal or opinion by a CPA or securities underwriter
about the reasonableness of the share repurchase price:
According to the opinion of Grand Fortune Securities Co., Ltd.,
the price range for this share buyback is reasonable and
complies with relevant regulations.
Based on the evaluation, the impact on the Company’s financial
structure, net value per share, earnings per share (EPS),
return on equity (ROE), current ratio, quick ratio, and cash
flow is not significant to the Company’s overall financial
condition or shareholders' equity.
18.Any other matters stipulated by the SFB:None.

Speech Date

2026/03/31

Theme

Board of Directors resolved to supplement the notice for the 2026 Annual General Shareholders’ Meeting (Additions to the meeting agenda)

Fact Date

2026-03-30

Describe

1.Date of the board of directors' resolution：2026/03/30
2.Shareholders meeting date：2026/05/20
3.Shareholders meeting location：Cowealth Center of 23F, No. 76,Sec. 2, Dunhua S. Rd., Da’an Dist.,
Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting)：physical shareholders' meeting
5.Cause for convening the meeting (1)：Report item(s)
(1)：2025annual business report
(2)：Audit Committee's review of the 2025 annual final accounting books
and statements
(3)：Report on 2025 employees' and directors' remuneration
(4)：Report on 2025 director compensation
(5)：Report on communications between the Audit Committee and the Head of
Internal Audit for 2025
(6)：Report on the 2026 concrete implementation plan for sustainable
development
(7)：Report on the 2026 share buyback progress
6.Cause for convening the meeting (2)：Ratification Item(s)
(1)：2025 annual financial statements and business report
(2)：2025 earnings distribution
7.Cause for convening the meeting (3)：Discussion Item(s)
(1)：Amendments to the "Articles of Association"
(2)：Amendments to the "Procedures for Acquisition or Disposal of Assets
Management"
8.Cause for convening the meeting (4)：Election Item
(1)：Proposal for Full Re-election of the Board of Directors
9.Cause for convening the meeting (5)：Other Proposal(s)
(1)：Removal of Non-Compete Restrictions for the 9th Board Directors of the Company
10.Extemporary Motions：
11.Book closure starting date：2026/03/22
12.Book closure ending date：2026/05/20
13.Any other matters that need to be specified：In accordance with the laws of the Republic of China, the
following matters related to the acceptance of shareholder
proposals in writing are established:
(1)Acceptance period: From March 6, 2026, to March 16, 2026.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Cowealth Holing Company
(4) Proposal Eligibility: Shareholders who hold more than 1% of
the total issued shares (whether individually or collectively).
(5) Proposal Method:
Shareholders intending to submit a proposal must do so in
writing by 5:00 PM on March 16, 2026, and each shareholder may
submit only one proposal. Proposals exceeding one item will not
be included in the agenda. Each proposal shall be limited to 300
Chinese characters; proposals exceeding this limit will not be
included in the agenda.
(6) Other Matters Related to Shareholder Proposals: Any matters
not covered regarding shareholder proposals will be handled
according to relevant laws and regulations. Whether or not a
proposal will be excluded from the agenda according to the
company's articles of association will be reviewed by the board
of directors after the proposal acceptance period has ended.
The detailed content of the accepted proposals will be based on
the company's public announcements on the Market Observation
Post System.
For this shareholder meeting, shareholders will exercise
their voting rights electronically. Relevant details are as
follows:
(1) Voting Period: Extended from March 6, 2026, to March 26, 2026.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(Taiwan Branch of Cowealth Holing Company)
(3) Proposal Eligibility: Shareholders who hold more than 1% of
the total issued shares (whether individually or collectively).
(4) Nomination Method:
There are four director positions and four independent director
positions to be elected. Shareholders intending to nominate
candidates for directors (including independent directors) must
submit a written nomination by 5:00 PM on March 26, 2026,
including the nominator's information and the nominee's name,
educational and professional background, and supporting
documents demonstrating compliance with the qualifications for
independent directors. Nominations exceeding the number of
positions to be elected, or nominees not meeting statutory
qualifications, will not be included in the candidate list.

Electronic Voting for the Shareholders' Meeting
(1) Voting Period: From April 20, 2026, to May 17, 2026.
(2) Electronic Voting Platform: Taiwan Depository & Clearing
Corporation, website: https://www.stockvote.com.tw

Speech Date

2026/03/31

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for February 2026

Fact Date

2026-03-31

Describe

1.Date of occurrence of the event:2026/03/31
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of February, the Company's accounts receivable balance
is NT$3,719,979 thousand (including overdue accounts receivable
of NT$1,973,713 thousand and non-overdue accounts receivable
of NT$1,746,266 thousand), accounting for 53.50% of total assets
and 480.31% of Common Stock. The amount recieved in February
was NT$212,314 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Since 2026, the Company has strengthened its accounts receivable
collection mechanism. For overdue accounts and customers with
potential bad debt risks, the Chairman & CEO, CFO, and Financial
Analysis Manager are now responsible for tracking and supervision
based on the transaction amounts and risk levels.
The collection amount in February significantly increased by 56%
compared to the previous month. Moving forward, the Company will
continue to implement collection measures and enhance accounts
receivable management to mitigate overall credit risk and improve the
efficiency of capital recovery.

Speech Date

2026/03/13

Theme

Board of Directors resolved to supplement notice for 2026 Annual General Shareholders' Meeting (Regarding Nominations for Directors and Independent Directors)

Fact Date

2026-03-13

Describe

1.Date of the board of directors' resolution：2026/03/13
2.Shareholders meeting date：2026/05/20
3.Shareholders meeting location：Cowealth Center of 23F, No. 76,Sec. 2, Dunhua S. Rd., Da’an Dist.,
Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting)：physical shareholders' meeting
5.Cause for convening the meeting (1)：Report item(s)
(1)：2025annual business report
(2)：Audit Committee's review of the 2025 annual final accounting
books and statements
(3)：Report on 2025 employees' and directors' remuneration
(4)：Report on 2025 director compensation
6.Cause for convening the meeting (2)：Ratification Item(s)
(1)：2025 annual financial statements and business report
(2)：2025 earnings distribution
7.Cause for convening the meeting (3)：Discussion Item(s)
(1)：Amendments to the "Articles of Association"
(2)：Amendments to the "Procedures for Acquisition or Disposal of
Assets Management"
(3)：Amendments to the "The Rules of Procedure for Shareholders Meetings"
8.Cause for convening the meeting (4)：Election Item
(1)：Proposal for Full Re-election of the Board of Directors
9.Cause for convening the meeting (5)：Other Proposal(s)
(1)：Removal of Non-Compete Restrictions for the 9th Board Directors
of the Company
10.Extemporary Motions：
11.Book closure starting date：2026/03/22
12.Book closure ending date：2026/05/20
13.Any other matters that need to be specified：In accordance with the laws of the Republic of China, the following
matters related to the acceptance of shareholder proposals in writing
are established:
(1) Acceptance period: From March 6, 2026, to March 16, 2026.
(2) Acceptance location: 23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Cowealth Holing Company
(4) Proposal Eligibility: Shareholders who hold more than 1% of the
total issued shares (whether individually or collectively).
(5) Proposal Method:
Shareholders intending to submit a proposal must do so in writing
by 5:00 PM on March 16, 2026, and each shareholder may submit only
one proposal. Proposals exceeding one item will not be included in
the agenda. Each proposal shall be limited to 300 Chinese
characters; proposals exceeding this limit will not be included in
the agenda.
(6) Other Matters Related to Shareholder Proposals: Any matters not
covered regarding shareholder proposals will be handled according
to relevant laws and regulations. Whether or not a proposal will
be excluded from the agenda according to the company's articles of
association will be reviewed by the board of directors after the
proposal acceptance period has ended. The detailed content of the
accepted proposals will be based on the company's public
announcements on the Market Observation Post System.

For this shareholder meeting, shareholders will exercise their voting
rights electronically. Relevant details are as follows:
(1) Voting Period: Extended from March 6, 2026, to March 26, 2026.
(2) Acceptance location: 23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da'an Dist., Taipei City 106485, Taiwan (R.O.C.)
(Taiwan Branch of Cowealth Holing Company)
(3) Proposal Eligibility: Shareholders who hold more than 1% of the
total issued shares (whether individually or collectively).
(4) Nomination Method:
There are four director positions and four independent director
positions to be elected. Shareholders intending to nominate
candidates for directors (including independent directors) must
submit a written nomination by 5:00 PM on March 26, 2026, including
the nominator's information and the nominee's name, educational and
professional background, and supporting documents demonstrating
compliance with the qualifications for independent directors.
Nominations exceeding the number of positions to be elected, or
nominees not meeting statutory qualifications, will not be included
in the candidate list.

Electronic Voting for the Shareholders' Meeting
(1) Voting Period: From April 20, 2026, to May 17, 2026.
(2) Electronic Voting Platform: Taiwan Depository & Clearing
Corporation, website: https://www.stockvote.com.tw

Speech Date

2026/03/13

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the year of 2025

Fact Date

2026-03-13

Describe

1.Date of the board of directors submitted or approved:2026/03/13
2.Date of the audit committee approved:2026/03/13
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2025/01/01~2025/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):2,956,257
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):392,176
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(275,424)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(285,297)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(331,106)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(246,557)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(3.18)
11.Total assets end of the period (thousand NTD):7,042,105
12.Total liabilities end of the period
(thousand NTD):1,985,415
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,870,165
14.Any other matters that need to be specified:None

Speech Date

2026/03/13

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2026-03-13

Describe

1.Date of occurrence of the event:2026/03/13
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 54.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the 2025 Annual Report and its Summary
of the Company
2、Resolutions Regarding the 2025 Board of Directors' Work Report
of the Company
3、Resolutions Regarding the 2025 Independent Directors' Performance Report
of the Company
4、Resolutions Regarding the Self-assessment of Independence of
Independent Directors
5、Resolutions Regarding the 2025 General Manager's Work Report
of the Company
6、Resolutions Regarding the 2025 Audit Committee's Performance Report
of the Company
7、Resolutions Regarding the Performance Evaluation Report of the
Accounting Firm for the Year 2025 and the Report on the Supervisory
Duties Performed by the Audit Committee
8、Resolutions Regarding the 2025 Financial Statements Report of the Company
9、Resolutions Regarding the 2025 Internal Control Evaluation Report of the
Company
10、Resolutions Regarding the Special Report on the Utilization of Raised
Funds and its Actual Usage in 2025
11、Resolutions Regarding the 2026 Audit Plan of the Company
12、Resolutions Regarding Amend the Director Compensation Management
Policy
13、Resolutions Regarding the 2026 Remuneration Plan for the company's
directors of the Company
14、Resolutions Regarding the 2026 Compensation Plan for Senior Management
Personnel of the Company
15、Resolutions Regarding the Proposed Profit Distribution Plan for the
Year 2025
16、Resolutions Regarding the Plan for the Guarantee Quota for the Year 2026
of the Company
17、Resolutions Regarding the company's application for credit facilities
from banks and other financial institutions.
18、Resolutions Regarding the company's use of temporarily idle self-owned
funds for entrusted wealth management.
19、Resolutions Regarding the Proposal to Convene the 2025 Annual General
Meeting of Shareholders
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2026/03/13

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolution by the Board of Directors not to Distribute Dividends

Fact Date

2026-03-13

Describe

1.Date of the board of directors resolution:2026/03/13
2.Type and monetary amount of dividend distribution:
Not to Distribute Dividends
3.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2026/03/13

Theme

Announcement of Board of Directors' Resolution Not to Distribute Dividends

Fact Date

2026-03-13

Describe

1.Date of the board of directors resolution:2026/03/13
2.Year or quarter which dividends belong to :2025
3.Period which dividends belong to:2025/01/01~2025/12/31
4.Appropriations of earnings in cash dividends to shareholders (NT$
per share):0
5.Cash dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
6.Total amount of cash dividends to shareholders (NT$):0
7.Appropriations of earnings in stock dividends to shareholders (NT$
per share):0
8.Stock dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
9.Total amount of stock dividends to shareholders (shares):0
10.Any other matters that need to be specified:None
11.Per value of common stock:NT$10

Speech Date

2026/03/05

Theme

Announcement of the Board of Directors meeting date for the Consolidated Financial Report for the year of 2025

Fact Date

2026-03-05

Describe

1.Date of a notice of the board of directors meeting is issued:2026/03/05
2.Expected date of the board of directors meeting is convened:2026/03/13
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:The Consolidated Financial Report for the year of 2025
4.Any other matters that need to be specified:None

Speech Date

2026/03/02

Theme

Board of Directors resolved to convene the 2026 Annual General Shareholders’ Meeting

Fact Date

2026-03-02

Describe

1.Date of the board of directors' resolution：2026/03/02
2.Shareholders meeting date：2026/05/20
3.Shareholders meeting location：Cowealth Center of 23F, No. 76,Sec. 2, Dunhua S. Rd.,
Da’an Dist., Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting)：physical shareholders' meeting
5.Cause for convening the meeting (1)：Report item(s)
(1)：2025 annual business report
(2)：Audit Committee's review of the 2025 annual final accounting books
and statements
(3)：Report on 2025 employees' and directors' remuneration
(4)：Report on 2025 director compensation
6.Cause for convening the meeting (2)：Ratification Item(s)
(1)：2025 annual financial statements and business report
(2)：2025 earnings distribution
7.Cause for convening the meeting (3)：Discussion Item(s)
(1)：Amendments to the "Articles of Association"
(2)：Amendments to the "Procedures for Acquisition or Disposal of
Assets Management"
(3)：Amendments to the "The Rules of Procedure for Shareholders Meetings"
8.Cause for convening the meeting (4)：Election Item
(1)：Proposal for Full Re-election of the Board of Directors
9.Extemporary Motions：
10.Book closure starting date：2026/03/22
11.Book closure ending date：2026/05/20
12.Any other matters that need to be specified：In accordance with the laws of the Republic of China,
the following matters related to the acceptance of shareholder
proposals in writing are established:

(1)Acceptance period: from March 7, 2025 to March 17, 2025.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd.,
Da’an Dist., Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Allied Healthcare
Medical Equipment Co., Ltd., a company incorporated in the
Cayman Islands.
(4) Proposal Eligibility: Shareholders who hold more than 1% of
the total issued shares (whether individually or collectively).
(5) Proposal Method:

• Any proposal submitted by a shareholder must be made in writing
and submitted no later than 17:00 on March 16, 2026, and shall be
limited to one proposal only. If more than one proposal is
submitted, none will be included in the meeting agenda.
Proposals shall be limited to 300 words; proposals exceeding
300 words will not be included in the agenda.

• Shareholders intending to nominate candidates for director
(including independent director) positions shall submit their
nominations in writing by 17:00 on March 16, 2026, together with
documentation specifying the nominator’s information and the
nominee’s name,education and work experience, and evidence
demonstrating qualifications for independent director
eligibility. If the number of nominees exceeds the number of
available seats or the nominees do not meet statutory
qualification requirements, they will not be included in the
candidate list

(6) Other Matters Related to Shareholder Proposals: Any matters
not covered regarding shareholder proposals will be handled
according to relevant laws and regulations. Whether or not a
proposal will be excluded from the agenda according to the
company’s articles of association will be reviewed by the
board of directors after the proposal acceptance period has
ended. The detailed content of the accepted proposals will
be based on the company’s public announcements on the Market
Observation Post System.

For this shareholder meeting, shareholders will exercise their
voting rights electronically. Relevant details are as follows:
(1) Voting Period: From April 20, 2026, to May 17, 2026.
(2) Electronic Voting Platform: Taiwan Depository & Clearing
Corporation, website: https://www.stockvote.com.tw

Speech Date

2026/03/02

Theme

Announcement of the Board of Directors’ Appointment of the Corporate Governance Officer

Fact Date

2026-03-02

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Corporate Governance Officer
2.Date of occurrence of the change:2026/03/02
3.Name, title, and resume of the previous position holder:N/A
4.Name, title, and resume of the new position holder:
Cathy, Juan / Accounting Officer
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):new replacement
6.Reason for the change:new replacement
7.Effective date:2026/03/02
8.Any other matters that need to be specified:N/A

Speech Date

2026/03/02

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the Regarding Civil Litigation Matters

Fact Date

2026-03-02

Describe

1.Parties to the legal matter:
Plaintiff/ Defendant: Guangdong Second Provincial General Hospital
Plaintiff/ Defendant: Cowealth Medical China Co., Ltd.
2.Name of the court or punishing agency of the legal matter:
Haizhu District People’s Court of Guangzhou
3.Reference/Case number of relevant documents of the legal matter:
Case No. (2025) Yue 0105 Min Chu No. 42651
4.Date of occurrence of the event:2026/03/02
5.Details of occurrence (including the matter under dispute):
The Company’s subsidiary, Cowealth Medical China Co., Ltd., (hereinafter
referred to as “The Company”) and Guangdong Second People’s Hospital
(hereinafter referred to as the “Hospital”) established a five-year reagent
supply chain integration cooperation in June 2020. Due to the Hospital’s
breach of contract and the failure of negotiations, The Company filed a
lawsuit with the Haizhu District People’s Court of Guangzhou Municipality
regarding a dispute over the reagent sales contract, with an amount in
dispute of RMB 48,878,323.02. The Haizhu District People’s Court of
Guangzhou Municipality accepted the case on April 28, 2025. On
September 10, 2025, the Hospital filed a counterclaim in relation to the
same reagent sales contract dispute, with a counterclaim amount of RMB
5,836,146.
In 2018, The Company and the Hospital commenced cooperation on the
clinical trial of radiotherapy equipment and subsequently reached an
intention for procurement and retention of the equipment. As the Hospital
ultimately failed to perform its obligation to procure the radiotherapy
equipment, resulting in losses to the Company, and negotiations between
the parties failed, The Company separately filed a lawsuit in April 2025 with
the Pudong New Area People’s Court of Shanghai Municipality regarding a
dispute over the radiotherapy equipment sales contract, with an amount in
dispute of RMB 50,877,893.90. The Pudong New Area People’s Court of
Shanghai Municipality accepted the case on August 20, 2025.
In respect of the same radiotherapy equipment sales contract dispute, the
Hospital also filed a lawsuit with the Haizhu District People’s Court of
Guangzhou Municipality, alleging that The Company’s delay in delivering
the equipment caused losses to the Hospital, with an amount in dispute of
RMB 30,362,772.84. On February 27, 2026, The Company a received a
Summons (Case No. (2025) Yue 0105 Min Chu No. 42651) and other
litigation materials issued by the Haizhu District People’s Court of
Guangzhou Municipality.
6.Handling procedure:
The Company has engaged legal counsel to handle the subsequent
proceedings in order to fully safeguard the legitimate rights and interests
of the Company and all its shareholders.
7.Impact on the Company’s finance and business and projected amount:
The case has not yet been heard in court, and the final judgment remains
uncertain. The impact on the Company’s current or subsequent profits
cannot be accurately estimated at this stage. The Company will carry out
the relevant accounting treatment in accordance with the actual progress of
the case and the requirements of accounting standards. The Company will
duly fulfill its information disclosure obligations regarding subsequent
developments of this litigation matter.
8.Countermeasures and improvement status:
The Company has appointed legal counsel to take the necessary measures
in accordance with the relevant litigation procedures and regulations.
9.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 2
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
For details of the above announcement, please refer to the disclosure
website of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2026/02/25

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for January 2026

Fact Date

2026-02-25

Describe

1.Date of occurrence of the event:2026/02/25
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of January, the Company's accounts receivable balance
is NT$3,643,529 thousand (including overdue accounts receivable
of NT$1,697,248 thousand and non-overdue accounts receivable
of NT$1,946,281 thousand), accounting for 52.40% of total assets
and 470.44% of Common Stock. The amount recieved in January
was NT$136,078 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Since 2026, the Company has strengthened its accounts receivable
collection mechanism. For overdue accounts and customers with
potential bad debt risks, the Chairman & CEO, CFO, and Financial
Analysis Manager are now responsible for tracking and supervision
based on the transaction amounts and risk levels.
Currently, some hospitals have proposed concrete repayment plans in
accordance with the Company’s collection mechanism. Moving forward,
the Company will continue to implement collection measures and
enhance accounts receivable management to mitigate overall credit risk
and improve the efficiency of capital recovery.

Speech Date

2026/01/30

Theme

(Correction to Jan 29 Announcement) Announcement of the Change of Corporate Governance Officer

Fact Date

2026-01-29

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Corporate Governance Officer
2.Date of occurrence of the change:2026/01/29
3.Name, title, and resume of the previous position holder:
Qiao, Jessica/ Corporate Governance Officer
4.Name, title, and resume of the new position holder:
To be appointed by the Board
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):Resignation
6.Reason for the change:Resignation
7.Effective date:2026/01/29
8.Any other matters that need to be specified:
The official appointees will be announced after the
formal appointment by the Board of Directors.

Speech Date

2026/01/29

Theme

Announcement of the change of Corporate Governance Officer

Fact Date

2026-01-29

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Corporate Governance Officer
2.Date of occurrence of the change:2026/01/29
3.Name, title, and resume of the previous position holder:
Qiao, Jessica/ Corporate Governance Officer
4.Name, title, and resume of the new position holder:
To be appointed by the Board
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):Resignation
6.Reason for the change:Resignation
7.Effective date:2026/01/29
8.Any other matters that need to be specified:
The official appointees will be announced after the
formal appointment by the Board of Directors.

Speech Date

2026/01/22

Theme

Correction to the Company's reported information on Endorsements and Guarantees for December 2025

Fact Date

2026-01-22

Describe

1.Date of occurrence of the event:2026/01/22
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head
office” or ”subsidiaries”):
head office and its subsidiaries(”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
Correction to the Company's reported information on Endorsements and
Guarantees for December 2025
6.Information items/ statements to be corrected:
The Company's reported information on Endorsements and Guarantees
for December 2025
7.Amounts/ contents/ number of page to be corrected:
Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Colab Reserch & Development Inc.
Amount of increase (decrease) for the individual subsidiary this month:
129,645 thousand

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Coaim Information Technology Co.,Ltd.
Amount of increase (decrease) for the individual subsidiary this month:
129,645 thousand

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: CHM Consulting Co., Ltd.
Amount of increase (decrease) for the individual subsidiary this month:
43,215 thousand

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Royal Seal Holding Co., Limited
Amount of increase (decrease) for the individual subsidiary this month:
864,300 thousand

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Cowealth Medical Shanghai Co., Ltd.
Amount of increase (decrease) for the individual subsidiary this month:
129,645 thousand
8.Amounts/ contents/ number of page after correction:
Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Colab Reserch & Development Inc.
Amount of increase (decrease) for the individual subsidiary this month:0

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Coaim Information Technology Co.,Ltd.
Amount of increase (decrease) for the individual subsidiary this month:0

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: CHM Consulting Co., Ltd.
Amount of increase (decrease) for the individual subsidiary this month:0

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Royal Seal Holding Co., Limited
Amount of increase (decrease) for the individual subsidiary this month:0

Name of the company making the endorsement/guarantee:
Cowealth Medical China Co., Ltd.
Endorsement/guarantee recipient: Cowealth Medical Shanghai Co., Ltd.
Amount of increase (decrease) for the individual subsidiary this month:0
9.Countermeasures:
To proceed in accordance with the regulations specified in the letter.
10.Any other matters that need to be specified:None

Speech Date

2026/01/16

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for December 2025

Fact Date

2026-01-16

Describe

1.Date of occurrence of the event:2026/01/16
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of November, the Company's accounts receivable balance
is NT$3,456,606 thousand (including overdue accounts receivable
of NT$1,536,638 thousand and non-overdue accounts receivable
of NT$1,919,968 thousand), accounting for 49.94% of total assets
and 446.30% of Common Stock. The amount recieved in December
was NT$411,295 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
The Company has actively promoted the collection of accounts
receivable, resulting in a decrease of 93,855 thousand in the balance for
the current quarter compared to the previous quarter. Additionally, the
actions and strengthen its accounts receivable management mechanism
to reduce credit risk.

Speech Date

2026/01/01

Theme

Subsidiary Cowealth (HK) proposes to dispose of equity in material subsidiary Cowealth (China).

Fact Date

2025-12-31

Describe

1.Name of the securities:
Equity of Cowealth (China) Medical Technology Co., Ltd.
2.Trading date:2025/12/24~2025/12/31
3.Amount, unit price, and total monetary amount of the
transaction:
(1).Transaction volume: 3,980,000 shares
(2).Unit price: Average price of RMB 24.923 per unit
(3).Total transaction amount: RMB 99,193,707
(approximately NTD 438,713,927)
4.Gain (or loss) through disposal (not applicable in
case of acquisition of securities):
Pursuant to IFRS, the Company retains control over the
subsidiary after the disposal; thus, no gain or loss is
recognized.
5.Relationship with the underlying company of the trade:
Material subsidiary of the Company
6.Current cumulative amount held, monetary value, and
shareholding percentage of cumulative holdings of the
securities being traded (including the current trade),
and status of any restriction of rights (e.g., pledges):
Cumulative amount held:
(1).Cumulative amount held: 218,937,885 shares
(2).Monetary value: Based on Cowealth (China)'s closing
price on Dec 31, the cumulative total amount is
NTD 23,197,463.90
(3).Shareholding percentage: 54%
(4).Status of any restriction of rights: None
7.Current ratio of securities investment (including the
current trade) to the total assets and equity attributable
to owners of parent as shown in the most recent financial
statement and working capital as shown in the most recent
financial statement as of the present, as listed in the
Regulations Governing the Acquisition and Disposal of
Assets by Public Companies: Ratio to total assets:6.60%
Ratio to equity attributable to owners of parent:17.06%
Working capital:NTD 3,606,029 thousand
8.Concrete purpose of the acquisition or disposal:
To respond to the current competitive market environment
and business development needs, and to enhance the Group's
overall operational efficiency and shareholder returns by
adjusting the shareholding structure.
9.Whether the directors expressed any objection to
the current transaction:None
10.Whether the counterparty of the current transaction
is a related party:Yes
11.Trading counterparty and its relationship to the
Company:Material subsidiary of the Company
12.Date of the board of directors’ resolution:2025/11/21
13.Date of ratification by supervisors or approval by
the audit committee:2025/11/21
14.Any other matters that need to be specified:
(1).On October 17, 2025, the Company received an approval
letter from the Taipei Exchange (TPEx) regarding the
adjustment to include ”the disposal of existing shareholdings
in Cowealth (China)” to reduce the ownership in Cowealth
(China) to above 51%.
(2).The Company's subsidiary, Cowealth (Hong Kong) Holding
Co., Ltd., currently holds 55% equity in Cowealth (China).
It proposes to dispose of equity not exceeding 4%, and the
Chairman is authorized with full authority to handle all
related matters.